These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6910423)

  • 21. Purification of high molecular weight kininogen and the role of this agent in blood coagulation.
    Saito H
    J Clin Invest; 1977 Sep; 60(3):584-94. PubMed ID: 893664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
    Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The regulation of human factor XIIa by plasma proteinase inhibitors.
    Pixley RA; Schapira M; Colman RW
    J Biol Chem; 1985 Feb; 260(3):1723-9. PubMed ID: 2578463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surface activation of factor XII (Hageman factor)--critical role of high molecular weight kininogen and another potentiator).
    Chan JY; Burrowes CE; Movat HZ
    Agents Actions; 1978 Jan; 8(1-2):65-72. PubMed ID: 636957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel sensitive assay for functional factor XII based on the generation of kallikrein-C1-inhibitor complexes in factor XII-deficient plasma by glass-bound factor XII.
    Dors DM; Nuijens JH; Huijbregts CC; Hack CE
    Thromb Haemost; 1992 Jun; 67(6):644-8. PubMed ID: 1509403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The inositol-phospholipid-accelerated activation of prekallikrein by activated factor XII at physiological ionic strength requires zinc ions and high-Mr kininogen.
    Schousboe I
    Eur J Biochem; 1990 Oct; 193(2):495-9. PubMed ID: 2226467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on human kininogens. I. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW)-kininogen.
    Nakayasu T; Nagasawa S
    J Biochem; 1979 Jan; 85(1):249-58. PubMed ID: 104988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification and characterization of two kinds of low molecular weight kininogens from rat (non-inflamed) plasma. One resistant and the second sensitive to rat glandular kallikreins.
    Enjyoji K; Kato H; Hayashi I; Oh-ishi S; Iwanaga S
    J Biol Chem; 1988 Jan; 263(2):965-72. PubMed ID: 3335530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in plasma levels of prekallikrein, kallikrein, high molecular weight kininogen and kallikrein inhibitors during lethal endotoxin shock in dogs.
    Gallimore MJ; Aasen AO; Amundsen E
    Haemostasis; 1978; 7(2-3):79-84. PubMed ID: 658781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced cofactor function of human high molecular weight kininogen induced by rat plasma kallikrein.
    Hoem NO; Briseid K
    Acta Pharmacol Toxicol (Copenh); 1985 Jul; 57(1):47-52. PubMed ID: 3850711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma.
    Mandle RJ; Colman RW; Kaplan AP
    Proc Natl Acad Sci U S A; 1976 Nov; 73(11):4179-83. PubMed ID: 1069308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prekallikrein activation in the adult respiratory distress syndrome.
    Schapira M; Gardaz JP; Py P; Lew PD; Perrin LH; Suter PM
    Bull Eur Physiopathol Respir; 1985; 21(3):237-41. PubMed ID: 3873975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of an esterolytic and kinin-forming kallikrein-alpha2-macroglobulin complex in human serum by treatment with acetone.
    Vogt V; Dugal B
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Jul; 294(1):75-84. PubMed ID: 63921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen.
    Kleniewski J; Donaldson VH
    J Lab Clin Med; 1987 Apr; 109(4):469-79. PubMed ID: 2950194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cold promoted activation and factor XII, prekallikrein and C1-inhibitor.
    Czendlik C; Lämmle B; Duckert F
    Thromb Haemost; 1985 Apr; 53(2):242-4. PubMed ID: 2410997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of aprotinin and C1-esterase inhibitor on activation of the plasma kallikrein-kinin system in vivo.
    Hoffmann H; Siebeck M; Thetter O; Fink E; Philapitsch A
    Prog Clin Biol Res; 1987; 236A():159-64. PubMed ID: 2441405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of factor XII, high-molecular-weight (HMW) kininogen and prekallikrein with sulfatide: analysis by fluorescence polarization.
    Shimada T; Kato H; Maeda H; Iwanaga S
    J Biochem; 1985 Jun; 97(6):1637-44. PubMed ID: 3928613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fujiwara trait: the first case of kininogen deficiency in Japan.
    Oh-Ishi S; Ueno A; Uchida Y; Katori M; Hayashi H; Koya H; Kitajima K; Kimura I
    Adv Exp Med Biol; 1979; 120B():93-9. PubMed ID: 517263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human plasma kallikrein: purification, enzyme characterization and quantitative determination in plasma.
    Heber H; Geiger R; Heimburger N
    Hoppe Seylers Z Physiol Chem; 1978 Jun; 359(6):659-69. PubMed ID: 97200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.